NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

[1]  D. Pe’er,et al.  Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer , 2020, Clinical Cancer Research.

[2]  A. Drilon,et al.  Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.

[3]  A. Shaw,et al.  Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. , 2019, The Lancet. Oncology.

[4]  Yue Du,et al.  Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. , 2019, Pharmacology & therapeutics.

[5]  A. Drilon,et al.  TRK inhibitors in TRK fusion-positive cancers , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Kengo Watanabe,et al.  The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models , 2019, Nature Communications.

[7]  Amanda R. Kulick,et al.  Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation , 2019, Nature Medicine.

[8]  S. C. Wang,et al.  Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Roland L. Dunbrack,et al.  Defining a new nomenclature for the structures of active and inactive kinases , 2019, Proceedings of the National Academy of Sciences.

[10]  A. Drilon,et al.  NTRK fusion-positive cancers and TRK inhibitor therapy , 2018, Nature Reviews Clinical Oncology.

[11]  M. Ladanyi,et al.  Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers. , 2018, JCO precision oncology.

[12]  A. Drilon,et al.  Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. , 2018, Cancer discovery.

[13]  P. Sorensen,et al.  Insulin-like growth factor 1 receptor stabilizes the ETV6–NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation , 2018, The Journal of Biological Chemistry.

[14]  Funda Meric-Bernstam,et al.  Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.

[15]  T. Kinoshita,et al.  Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model , 2018, Clinical Cancer Research.

[16]  Marissa Mattar,et al.  Establishing and Maintaining an Extensive Library of Patient-Derived Xenograft Models , 2018, Front. Oncol..

[17]  Ying Cheng,et al.  Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer , 2018 .

[18]  B. Taylor,et al.  A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. , 2017, Cancer discovery.

[19]  Ryohei Katayama,et al.  Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers , 2017, Molecular Cancer Therapeutics.

[20]  Lauren L. Ritterhouse,et al.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. , 2016, Cancer discovery.

[21]  Lauren L. Ritterhouse,et al.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer , 2016 .

[22]  M. Ladanyi,et al.  What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  M. Ladanyi,et al.  A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer , 2015, Clinical Cancer Research.

[24]  Manish B. Patel,et al.  Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  Gang Li,et al.  Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. , 2015, Cancer discovery.

[26]  Dara L Aisner,et al.  An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. , 2015, Cancer discovery.

[27]  Jennifer A. Smith,et al.  Meeting Report: Inaugural Chemotherapy-Induced Peripheral Neuropathy Symposium - Santa Barbara, CA, February 2015. , 2015, Cancer research.

[28]  A. Drilon,et al.  Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors , 2015, Proceedings of the National Academy of Sciences.

[29]  L. Stewart,et al.  Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2 , 2015, Molecular Cancer Therapeutics.

[30]  J. Fagin,et al.  Abstract 790: Altiratinib is a potent inhibitor of TRK kinases and is efficacious in TRK-fusion driven cancer models , 2015 .

[31]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[32]  Gert Vriend,et al.  New ways to boost molecular dynamics simulations , 2015, J. Comput. Chem..

[33]  B. Beno,et al.  A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design. , 2015, Journal of medicinal chemistry.

[34]  J. Engelman,et al.  Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer , 2014, Clinical Cancer Research.

[35]  A. Shaw,et al.  ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. , 2014, Clinical advances in hematology & oncology : H&O.

[36]  S. Lowe,et al.  Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins , 2013, Proceedings of the National Academy of Sciences.

[37]  Mari Mino-Kenudson,et al.  Acquired resistance to crizotinib from a mutation in CD74-ROS1. , 2013, The New England journal of medicine.

[38]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[39]  K. Shokat,et al.  The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. , 2011, Annual review of biochemistry.

[40]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[41]  Ashley L. Ringer,et al.  Models of S/π interactions in protein structures: Comparison of the H2S–benzene complex with PDB data , 2007, Protein science : a publication of the Protein Society.

[42]  Sungjoon Kim,et al.  Ba/F3 cells and their use in kinase drug discovery , 2007, Current opinion in oncology.

[43]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[44]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[45]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[46]  Janet M. Thornton,et al.  PDBsum more: new summaries and analyses of the known 3D structures of proteins and nucleic acids , 2004, Nucleic Acids Res..

[47]  P. Sorensen,et al.  Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. , 2002, Cancer cell.

[48]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[49]  Henrik Land,et al.  YASARA: A Tool to Obtain Structural Guidance in Biocatalytic Investigations. , 2018, Methods in molecular biology.

[50]  R. Roskoski.  Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. , 2016, Pharmacological research.